GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells | Science Advances
Typ-2-Diabetes: Dualer GIP/GLP-1-Rezeptoragonist Tirzepatid bewirkt bessere glykämische Kontrolle
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes - ScienceDirect
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models - Media Centre | EASD
Metabolic actions of GLP-1 and GIP on key target tissues. | Download Scientific Diagram
Tirzepatid in den USA zugelassen | PZ – Pharmazeutische Zeitung
![incretins_diabetes [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1rev.png?w=600&tok=8ead39 "incretins_diabetes [TUSOM | Pharmwiki]")
incretins_diabetes [TUSOM | Pharmwiki]
DE: Neuer Ansatzpunkt für die Entwicklung einer medikamentösen Behandlung von Adipositas und Typ-2-Diabetes | Pflege Professionell
GIP | Einfluss von GIP auf den Glukosestoffwechsel
GLP-1: Actions on Beta-cell Mass and Function
Blutzucker- und Gewichtsregulation bei Typ-2-Diabetes: Der duale GIP/GLP-1-Rezeptor-Agonist Tirzepatid ist Semaglutid überlegen
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text
GIP | Was ist GIP?
Neue Diabetemedikamente Typ-2-Diabetes - diabetes-news : diabetes-news
EASD 2018: benefits of GIP/GLP-1 receptor co-agonists in T2D
The role of GLP-1 and GIP in glucose homeostasis. Key defects in... | Download Scientific Diagram
Inkretinmimetika – Wikipedia
How May GIP Enhance the Therapeutic Efficacy of GLP-1?: Trends in Endocrinology & Metabolism
GIP and Glycemic Impact | Explore GIP
How May GIP Enhance the Therapeutic Efficacy of GLP-1?: Trends in Endocrinology & Metabolism
Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
New strategies for the treatment of obesity and metabolic dysfunctions
Efficacy and safety of LY3298176, a GIP/GLP-1 receptor co-agonist, in subjects with type 2 diabetes: a phase 2b study - Media Centre | EASD
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study | SpringerLink
Biology | Free Full-Text | Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
